Cue Biopharma is trading 5.1% down at $26.82 after a highly volatile session, with no new company-specific announcement or reliable catalyst identified for September 22.
- The September 20 CUE-221 Phase 2 results showed statistically significant efficacy and supported plans for a later-stage study.
- The broader biotech sector is higher, so sector strength does not clearly explain the company-specific decline.